Company Overview

Arrowhead Pharmaceuticals, Inc. is a publicly traded biotechnology company focused on the discovery and development of RNA interference (RNAi)–based medicines. The company operates within the biotechnology and pharmaceutical industries, specifically targeting diseases driven by the production of pathogenic proteins. Arrowhead’s core strategy is to design RNAi therapeutics that silence disease-causing genes at the source, with a primary focus on cardiometabolic, hepatic, pulmonary, and rare genetic diseases.

The company’s primary value drivers are its proprietary RNAi delivery platforms and a pipeline of clinical and preclinical drug candidates, most of which are wholly owned. Arrowhead does not currently generate product revenue and instead relies on research collaborations, licensing agreements, and equity financing to support operations. Founded in 2003 and originally focused on nanotechnology, Arrowhead pivoted in the late 2000s to RNAi therapeutics, evolving into a clinical-stage biotechnology company with multiple assets in human trials.

Business Operations

Arrowhead’s operations are centered on the research, development, and clinical advancement of RNAi therapeutics using its proprietary TRiM™ (Targeted RNAi Molecule) platform. The company generates revenue primarily through upfront payments, milestone payments, and research funding from strategic collaborations, while internal programs are advanced toward potential regulatory approval. Arrowhead’s pipeline includes candidates targeting conditions such as hypertriglyceridemia, dyslipidemia, nonalcoholic steatohepatitis, cystic fibrosis, and other cardiopulmonary and hepatic disorders.

The company conducts research and development internally and through contract research organizations, with clinical trials spanning the United States and international sites. Arrowhead has established partnerships with large pharmaceutical companies, including long-term collaborations with Amgen Inc. and Horizon Therapeutics plc (now part of Amgen Inc.), which provide external validation of its technology and non-dilutive capital. Arrowhead operates as a single reporting segment focused on RNAi therapeutics.

Strategic Position & Investments

Arrowhead’s strategic direction emphasizes advancing a broad, wholly owned clinical pipeline while selectively partnering assets to manage risk and fund innovation. Growth initiatives focus on expanding the application of its RNAi platform beyond liver-targeted diseases into extrahepatic tissues, including lung and muscle. This expansion is intended to differentiate Arrowhead from other RNAi-focused biotechnology firms that are more limited in tissue targeting.

The company has made targeted acquisitions and investments to strengthen its technology base, most notably the acquisition of Dicerna Pharmaceuticals, Inc. assets related to RNAi chemistry and intellectual property. Arrowhead also maintains equity interests and licensing relationships with early-stage biotechnology entities aligned with RNAi and gene-silencing technologies. Emerging areas of focus include chronic cardiometabolic diseases with large patient populations and orphan genetic disorders with high unmet medical need.

Geographic Footprint

Arrowhead Pharmaceuticals is headquartered in Pasadena, California, and operates primarily in North America. Its research, development, and corporate functions are largely based in the United States, with clinical trial activities extending into Europe and other international regions as required for global drug development.

While Arrowhead does not maintain large-scale commercial operations abroad, its global footprint is extended through international clinical trial sites, regulatory interactions, and partnerships with multinational pharmaceutical companies. The company’s strategic influence is primarily concentrated in developed pharmaceutical markets, reflecting its clinical-stage focus and regulatory strategy.

Leadership & Governance

Arrowhead is led by an experienced management team with deep expertise in biotechnology, drug development, and RNAi science. The leadership emphasizes long-term value creation through platform innovation, disciplined capital allocation, and retention of asset ownership through later stages of development.

Key executives include:

• Christopher R. Anzalone – President and Chief Executive Officer
• James C. Hamilton – Chief Financial Officer
• Bruce D. Given – Chief Operating Officer
• James N. Topper – Chief Scientific Officer
• David R. Corey – Senior Vice President, Biology

The company is governed by a board of directors with backgrounds in pharmaceuticals, finance, and biotechnology, supporting oversight, strategic planning, and compliance with public company governance standards.